GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Cyclically Adjusted PB Ratio

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Cyclically Adjusted PB Ratio : (As of May. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AVEO Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, AVEO Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.833/125.2265*125.2265
=0.833

Current CPI (Sep. 2022) = 125.2265.

AVEO Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201212 27.167 96.871 35.119
201303 27.230 98.209 34.721
201306 20.856 98.518 26.510
201309 16.433 98.790 20.831
201312 13.499 98.326 17.192
201403 12.297 99.695 15.446
201406 8.978 100.560 11.180
201409 6.559 100.428 8.179
201412 3.941 99.070 4.982
201503 2.653 99.621 3.335
201506 2.017 100.684 2.509
201509 4.104 100.392 5.119
201512 2.961 99.792 3.716
201603 1.704 100.470 2.124
201606 1.093 101.688 1.346
201609 0.466 101.861 0.573
201612 -0.253 101.863 -0.311
201703 0.445 102.862 0.542
201706 -1.654 103.349 -2.004
201709 -3.767 104.136 -4.530
201712 -3.445 104.011 -4.148
201803 -4.227 105.290 -5.027
201806 -3.819 106.317 -4.498
201809 -4.969 106.507 -5.842
201812 -2.153 105.998 -2.544
201903 -1.336 107.251 -1.560
201906 0.102 108.070 0.118
201909 1.167 108.329 1.349
201912 0.923 108.420 1.066
202003 0.436 108.902 0.501
202006 1.862 108.767 2.144
202009 1.559 109.815 1.778
202012 1.313 109.897 1.496
202103 2.108 111.754 2.362
202106 1.751 114.631 1.913
202109 1.490 115.734 1.612
202112 1.331 117.630 1.417
202203 1.072 121.301 1.107
202206 0.884 125.017 0.885
202209 0.833 125.227 0.833

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVEO Pharmaceuticals  (NAS:AVEO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
Jebediah Ledell officer: Chief Operating Officer C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey director, officer: President & CEO IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso officer: Chief Commercial Officer AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell 10 percent owner
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera officer: Chief Financial Officer 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring director AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Headlines

From GuruFocus

LG Chem Completes Acquisition of AVEO Oncology

By Stock market mentor Stock market mentor 01-19-2023

AVEO Oncology Stockholders Approve Acquisition by LG Chem

By Stock market mentor Stock market mentor 01-06-2023